<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Unlisted</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/D9354644-2A15-43E4-A1C9-D71131623DB2"><gtr:id>D9354644-2A15-43E4-A1C9-D71131623DB2</gtr:id><gtr:firstName>Daniel</gtr:firstName><gtr:surname>Hochhauser</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0000168"><gtr:id>46CD69C3-1955-4740-994C-8CD7D11CBCDF</gtr:id><gtr:title>Modulation of topoisomerase II transcription: novel strategies and therapeutic applications</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0000168</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:fund><gtr:end>2007-01-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2000-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>597025</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>School work experience</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:id>D0E1C5F4-1DA8-410C-A409-A2D8C8EE1C19</gtr:id><gtr:impact>School work experience 4 studentships for senior school students working on the project

MRC acknowledgement in all presentations and publications</gtr:impact><gtr:outcomeId>4401FA3E88A</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2006,2007,2008,2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>D7BDB303-E6A7-4DD8-9529-80BCBB6A666E</gtr:id><gtr:title>Polyamide curvature and DNA sequence selective recognition: use of 4-aminobenzamide to adjust curvature.</gtr:title><gtr:parentPublicationTitle>Medicinal chemistry (Shariqah (United Arab Emirates))</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/631d1de265ef68458523f99019546879"><gtr:id>631d1de265ef68458523f99019546879</gtr:id><gtr:otherNames>Lajiness J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1573-4064</gtr:issn><gtr:outcomeId>pm_16581_11_19442211</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D9B9A4A7-CFEA-4D0A-8EF9-2EC94BD483BC</gtr:id><gtr:title>Binding of f-PIP, a pyrrole- and imidazole-containing triamide, to the inverted CCAAT box-2 of the topoisomerase IIalpha promoter and modulation of gene expression in cells.</gtr:title><gtr:parentPublicationTitle>Bioorganic &amp; medicinal chemistry letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f4aeca7408a7f34902f73de58c9da31d"><gtr:id>f4aeca7408a7f34902f73de58c9da31d</gtr:id><gtr:otherNames>Le NM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0960-894X</gtr:issn><gtr:outcomeId>DA3DBEC7B75</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>68F41753-0004-41EC-9F77-58DB497B4648</gtr:id><gtr:title>Synthesis and evaluation of an intercalator-polyamide hairpin designed to target the inverted CCAAT box 2 in the topoisomerase IIalpha promoter.</gtr:title><gtr:parentPublicationTitle>Chembiochem : a European journal of chemical biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8b7336bc126cf12178b3c28113dc5154"><gtr:id>8b7336bc126cf12178b3c28113dc5154</gtr:id><gtr:otherNames>Flores LV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1439-4227</gtr:issn><gtr:outcomeId>2008431A404</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EB9FB0DC-E565-4D3C-9456-719952462A91</gtr:id><gtr:title>Modulation of topoisomerase IIalpha expression by a DNA sequence-specific polyamide.</gtr:title><gtr:parentPublicationTitle>Molecular cancer therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b5f707a6bdc2d15d0ca9d63e3ba65088"><gtr:id>b5f707a6bdc2d15d0ca9d63e3ba65088</gtr:id><gtr:otherNames>Hochhauser D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1535-7163</gtr:issn><gtr:outcomeId>A054CAFB0B6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BC4D56FF-9228-439E-8F79-93AA23E6AD8D</gtr:id><gtr:title>Inhibition of DNA binding of the NF-Y transcription factor by the pyrrolobenzodiazepine-polyamide conjugate GWL-78.</gtr:title><gtr:parentPublicationTitle>Molecular cancer therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/914d6201066eedb8fa0b4b8e881fe17b"><gtr:id>914d6201066eedb8fa0b4b8e881fe17b</gtr:id><gtr:otherNames>Kotecha M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1535-7163</gtr:issn><gtr:outcomeId>V2fEVQ1dfi3</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0000168</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>DD81206B-5EB4-4BCC-AEF7-808A64606E0E</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>